IMMX Utang jangka cendhak perusahaan Immix Biopharma

Geopolitical risks are hindering international trials for Immix Biopharma, Inc. (IMMX), while a lack of sales leaves the business dependent on external financing. Financial liabilities with a maturity of up to one year on the GURU.Markets chart soften this contrast, where the current amount is 0.00. The company is currently focusing on accelerating CAR-T asset trials through partnerships with medical centers.

For Immix Biopharma, Inc. (IMMX), whose viability depends on clinical trial outcomes and a high burn rate, liquidity control is a critical survival factor. By analyzing the short-term debt chart, an investor assesses obligations maturing within one year to differentiate strategic scaling of the R&D pipeline from a dangerous approach toward a cash crunch in the absence of stable revenue.